Claims for Patent: 6,927,024

Summary for Patent: 6,927,024

Title:	PCR assay
Abstract:	An oligonucleotide assay is useful for the detection of target compounds in samples which may contain the target compound.
Inventor(s):	Dodge; Anthony H. (San Mateo, CA), Meng; Yu-Ju G. (Albany, CA), Sims; Paul W. (San Mateo, CA), Sinicropi; Dominick V. (Menlo Park, CA), Williams; P. Mickey (Half Moon Bay, CA), Wong; Wai Lee (Los Altos Hills, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	09/449,204
Patent Claims:	1. A method for quantitating or detecting the presence of a target molecule in a sample which contains the target molecule and a nuclease, comprising: (a) exposing the sample to a capture antibody or target molecule binding fragment thereof of which binds to the target molecule under conditions whereby a capture antibody:target molecule or a target molecule binding fragment:target molecule complex is formed; (b) adding to the complex from step (a), an RNA or DNA aptamer detector molecule which binds to the target molecule to form a capture antibody:target molecule:aptamer or a target molecule binding fragment:target molecule:aptamer ternary complex; (c) washing the complex from step (a) or (b) or both to remove said nuclease; (d) when the aptamer is an RNA detector molecule, reverse transcribing the RNA to DNA; (e) amplifying the DNA aptamer or DNA obtained by step (d) by PCR amplification; and (f) quantitating or detecting the PCR amplified DNA using a detectable non-primer probe which binds to the DNA using real time PCR during PCR amplification; wherein quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule. 2. The method of claim 1, further comprising washing the capture antibody:target molecule complex to remove unbound sample after step (a). 3. The method of claim 1, wherein the capture antibody is bound to a solid support or carrier during step (a) or (b). 4. The method of claim 3, wherein the solid support is a PCR tube. 5. The method of claim 1, wherein the capture antibody is in solution during step (a) or (b). 6. The method of claim 5, wherein the capture antibody is labeled with biotin and is bound to a streptavidin or avidin labeled support. 7. The method of claim 1, wherein the target molecule is an organic compound having a molecular weight of about 100 to about 1000 grams/mole. 8. The method of claim 1, wherein the target molecule is a protein or fragment thereof. 9. The method of claim 8, wherein the protein is a cytokine selected from the group consisting of growth hormone, insulin-like growth factors, human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), leutinizing hormone (LH), hematopoietic growth factor, vesicular endothelial growth factor (VEGF), hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-alpha, tumor necrosis factor-beta, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin vascular endothelial growth factor, integrin, nerve growth factors (NGFs), NGF-beta, platelet-growth factor, transforming growth factors (TGFs), TGF-alpha, TGF-beta, insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons, interferon-alpha, interferon-beta, interferon-gamma, colony stimulating factors (CSFs), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), thrombopoietin (TPO), interleukins (ILs), IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, LIF, SCF, neurturin (NTN) and kit-ligand (KL). 10. The method of claim 1, wherein the sample is selected from the group consisting of blood, serum, sputum, urine, semen, cerebrospinal fluid, bronchial aspirate and organ tissue. 11. The method of claim 1, wherein the detectable non-primer probe comprises a nucleic acid having a fluorescent dye label. 12. The method of claim 11, wherein the fluorescent dye label comprises two dyes, a reporter dye and a quencher dye, which fluoresce at different wavelengths. 13. The method of claim 1, wherein the nucleic acid detector molecule is RNA and the RNA detector molecule is reverse transcribed to form DNA before or during amplifying step d. 14. The method of claim 1, wherein the RNA detector molecule is reversed transcribed at a temperature sufficient to dissociate the detector molecule from the capture antibody:target molecule:aptamer ternary complex and reverse transcribe the RNA. 15. The method of claim 14, wherein the temperature is about 50 C to about 70 C. 16. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 1000 pg/mL. 17. The method of claim 16, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 100 pg/mL. 18. The method of claim 17, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 1 pg/mL. 19. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 100 to about 5000 pg/mL. 20. The method of claim 19, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 100 to about 1000 pg/mL. 21. The method of claim 19, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 1000 to about 5000 pg/mL. 22. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 3 to about 5000 pg/mL. 23. The method of claim 22, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 3 to about 1000 pg/mL. 24. The method of claim 22, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 3 to about 100 pg/mL. 25. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.4 to about 5000 pg/mL. 26. The method of claim 25, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.4 to about 1000 pg/mL. 27. The method of claim 26, wherein said quantitating or detecting the PCR amplified DNA quantities or detects the target molecule when present at a concentration of about 0.4 to about 100 pg/mL. 28. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 1 to about 5000 pg/mL. 29. The method of claim 28, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 1 to about 1000 pg/mL. 30. The method of claim 29, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 1 to about 100 pg/mL. 31. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 5000 pg/mL. 32. The method of claim 31, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 1000 pg/mL. 33. The method of claim 32, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 100 pg/mL. 34. The method of claim 1, wherein said quantitating or detecting the PCR amplified DNA quantities or detects the target molecule when present at a concentration of about 0.005 to about 5000 pg/mL. 35. The method of claim 34, wherein said quantities or detecting the PCR amplified DNA quantities or detects the target molecule when present at a concentration of about 0.005 to about 1000 pg/mL. 36. The method of claim 35, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.005 to about 100 pg/mL. 37. The method of claim 36, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.005 to about 1 pg/mL. 38. A method for quantitating or detecting the presence of a target molecule in a biological sample which contains the target molecule and a nuclease, comprising: (a) exposing the sample to a capture antibody or target molecule binding fragment thereof which binds to the target molecule under conditions whereby a capture antibody:target molecule or a target molecule binding fragment:target molecule complex is formed; (b) adding to the complex from step (a), an RNA or DNA aptamer detector molecule which binds to the target molecule to form a capture antibody:target molecule:aptamer or a target molecule binding fragment:target molecule:aptamer ternary complex; (c) washing the complex from step (a) or (b) or both to remove said nuclease; (d) when the aptamer is an RNA detector molecule, revere transcribing the RNA to DNA; (e) amplifying the DNA aptamer or DNA obtained by step (d) by PCR amplification; and (f) quantitating or detecting the PCR amplified DNA using a detectable non-primer probe which binds to the DNA using real time PCR during PCR amplification; wherein quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.005 to about 5000 pg/mL. 39. The method of claim 38, further comprising washing the capture antibody:target molecule complex to remove unbound sample after step (a). 40. The method of claim 38, wherein the capture antibody is bound to a solid support or carrier during step (a) or (b). 41. The method of claim 40, wherein the solid support is a PCR tube. 42. The method of claim 41, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 100 pg/mL. 43. The method of claim 42, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 1 pg/mL. 44. The method of claim 38, wherein the capture antibody is in solution during step (a) or (b). 45. The method of claim 44, wherein the capture antibody is labeled with biotin and is bound to a streptavidin or avidin labeled support. 46. The method of claim 38, wherein the target molecule is a protein or fragment thereof. 47. The method of claim 46, wherein the protein is a cytokine selected from the group consisting of growth hormone, insulin-like growth factors, human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), leutinizing hormone (LH), hematopoietic growth factor, vesicular endothelial growth factor (VEGF), hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-alpha, tumor necrosis factor-beta, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, nerve growth factors (NGFs), NGF-beta, platelet-growth factor, transforming growth factors (TGFs), TGF-alpha, TGF-beta, insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons, interferon-alpha, interferon-beta, interferon-gamma, colony stimulating factors (CSFs), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), thrombopoietin (TPO), interleukins (ILs), IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, LIF, SCF, neurturin (NTN) and kit-ligand (KL). 48. The method of claim 38, wherein the sample is selected from the group consisting of blood, serum, urine, semen, cerebrospinal fluid, bronchial aspirate and organ tissue. 49. The method of claim 38, wherein the detectable non-primer probe comprises a nucleic acid having a fluorescent dye label. 50. The method of claim 49, wherein the fluorescent dye label comprises two dyes, a reporter dye and a quencher dye, which fluorescent at different wavelengths. 51. The method of claim 38, wherein the nucleic acid detector molecule is RNA and the RNA detector molecule is reverse transcribed to form DNA before or during amplifying step d. 52. The method of claim 38, wherein the RNA detector molecule is reversed transcribed at a temperature sufficient to dissociate the detector molecule from the capture antibody:target molecule:aptamer ternary complex and reverse transcribe the RNA. 53. The method of claim 52, wherein the temperature is about 50 C to about 70 C. 54. The method of claim 38, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration equal to or less than 1000 pg/mL. 55. The method of claim 38, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 100 to about 5000 pg/mL. 56. The method of claim 38, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 3 to about 5000 pg/mL. 57. The method of claim 38, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.4 to about 5000 pg/mL. 58. The method of claim 38, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 5000 pg/mL. 59. The method of claim 58, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 1000 pg/mL. 60. The method of claim 59, wherein said quantitating or detecting the PCR amplified DNA quantitates or detects the target molecule when present at a concentration of about 0.03 to about 100 pg/mL.

Details for Patent 6,927,024

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2018-11-30